Literature DB >> 23303107

Epidemiology of two large measles virus outbreaks in Catalonia: what a difference the month of administration of the first dose of vaccine makes.

Núria Torner1, Andres Anton, Irene Barrabeig, Sara Lafuente, Ignasi Parron, César Arias, Neus Camps, Josep Costa, Ana Martínez, Roser Torra, Pere Godoy, Sofia Minguell, Glòria Ferrús, Carmen Cabezas, Ángela Domínguez.   

Abstract

Measles cases in the European Region have been increasing in the last decade; this illustrates the challenge of what we are now encountering in the form of pediatric preventable diseases. In Catalonia, autochthonous measles was declared eliminated in the year 2000 as the result of high measles-mumps-rubella vaccine (MMR) coverage for first and second dose (15 mo and 4 y) since the mid-1990s. From then on, sporadic imported cases and small outbreaks appeared, until in 2006-2007 a large measles outbreak affecting mostly unvaccinated toddlers hit the Barcelona Health Region. Consequently, in January 2008, first dose administration of MMR was lowered from 15 to 12 mo of age. A new honeymoon period went by until the end of 2010, when several importations of cases triggered new sustained transmission of different wild measles virus genotypes, but this time striking young adults. The aim of this study is to show the effect of a change in MMR vaccination schedule policy, and the difference in age incidence and hospitalization rates of affected individuals between both outbreaks.   Epidemiologic data were obtained by case interviews and review of medical records. Samples for virological confirmation and genotyping of cases were collected as established in the Measles Elimination plan guidelines. Incidence rate (IR), rate ratio (RR) and their 95% CI and hospitalization rate (HR) by age group were determined. Statistic z was used for comparing proportions. Total number of confirmed cases was 305 in the 2010 outbreak and 381 in the 2006-2007 outbreak; mean age 20 y (SD 14.8 y; 3 mo to 51 y) vs. 15 mo (SD 13.1 y; 1 mo to 50 y). Highest proportion of cases was set in ≥ 25 y (47%) vs. 24.2% in 2006 (p < 0.001). Differences in IR for ≤ 15 mo (49/100,000 vs. 278.2/100,000; RR: 3,9; 95%CI 2,9-5.4) and in overall HR 29.8% vs. 15.7% were all statistically significant (p < 0.001). The change of the month of age for the administration of the first MMR dose proved successful to protect infants. Yet, given the current epidemiological situation, continued awareness and efforts to reach young adult population, especially those at high risk of infection and transmission such as healthcare workers and travelers, are needed to stop the spread of the virus when importations occur.

Entities:  

Keywords:  elimination; genotype; measles; outbreak; vaccination coverage

Mesh:

Substances:

Year:  2013        PMID: 23303107      PMCID: PMC3891728          DOI: 10.4161/hv.23265

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  31 in total

1.  Humoral and cellular immune responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen.

Authors:  Patricia O Viana; Erika Ono; Maristela Miyamoto; Reinaldo Salomao; Beatriz T Costa-Carvalho; Lily Y Weckx; Maria Isabel de Moraes-Pinto
Journal:  J Clin Immunol       Date:  2010-04-20       Impact factor: 8.317

2.  Proceedings of the Global Technical Consultation to assess the feasibility of measles eradication, 28-30 July 2010.

Authors: 
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

3.  Nosocomial transmission of measles among healthcare workers, Bulgaria, 2010.

Authors:  R Komitova; A Kunchev; Z Mihneva; L Marinova
Journal:  Euro Surveill       Date:  2011-04-14

4.  Ongoing measles outbreak, Geneva, Switzerland, January to March 2011.

Authors:  E Delaporte; J L Richard; C A Wyler Lazarevic; O Lacour; M Girard; C Ginet; A Iten; P Sudre
Journal:  Euro Surveill       Date:  2011-03-10

5.  Outbreak of measles in France shows no signs of abating.

Authors:  Paul Benkimoun
Journal:  BMJ       Date:  2011-05-20

6.  Measles among healthcare workers: a potential for nosocomial outbreaks.

Authors:  E Botelho-Nevers; N Cassir; P Minodier; R Laporte; P Gautret; S Badiaga; D J Thiberville; L Ninove; R Charrel; P Brouqui
Journal:  Euro Surveill       Date:  2011-01-13

7.  Measles and rubella elimination initiatives in the Americas: lessons learned and best practices.

Authors:  Carlos Castillo-Solorzano; Christina Marsigli; M Carolina Danovaro-Holliday; Cuauhtémoc Ruiz-Matus; Gina Tambini; Jon Kim Andrus
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

8.  Vaccination coverage in indigenous and immigrant children under 3 years of age in Catalonia (Spain).

Authors:  E Borràs; A Domínguez; J Batalla; N Torner; N Cardeñosa; M Nebot; A Plasencia; L Salleras
Journal:  Vaccine       Date:  2007-01-22       Impact factor: 3.641

9.  Measles outbreak in adults in Italy.

Authors:  Matteo Bassetti; Eva Schenone; Anna Calzi; Marco Camera; Laura Valle; Filippo Ansaldi; Gabriella Pagano; Claudio Viscoli
Journal:  Infez Med       Date:  2011-03

10.  Large outbreak of measles in a community with high vaccination coverage: implications for the vaccination schedule.

Authors:  Angela Domínguez; Nuria Torner; Irene Barrabeig; Ariadna Rovira; Cristina Rius; Joan Cayla; Elsa Plasencia; Sofia Minguell; M Rosa Sala; Ana Martínez; Josep Costa; Mar Mosquera; Carmen Cabezas
Journal:  Clin Infect Dis       Date:  2008-11-01       Impact factor: 9.079

View more
  9 in total

1.  Implication of health care personnel in measles transmission.

Authors:  Núria Torner; Ruben Solano; Cristina Rius; Angela Domínguez; The Measles Elimination Program Surveillance Network Of Catalonia Spain
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

2.  Results of the rubella elimination program in Catalonia (Spain), 2002-2011.

Authors:  Irene Barrabeig; Nuria Torner; Ana Martínez; Gloria Carmona; Pilar Ciruela; Joan Batalla; Josep Costa; Sergi Hernández; Luis Salleras; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2013-01-08       Impact factor: 3.452

Review 3.  A global perspective of vaccination of healthcare personnel against measles: systematic review.

Authors:  Amy Parker Fiebelkorn; Jane F Seward; Walter A Orenstein
Journal:  Vaccine       Date:  2013-11-24       Impact factor: 3.641

4.  Fatal measles virus infection prevented by brain-penetrant fusion inhibitors.

Authors:  Jeremy C Welsch; Aparna Talekar; Cyrille Mathieu; Antonello Pessi; Anne Moscona; Branka Horvat; Matteo Porotto
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

Review 5.  Hospital preparedness in community measles outbreaks-challenges and recommendations for low-resource settings.

Authors:  Sadia Shakoor; Fatima Mir; Anita K M Zaidi; Afia Zafar
Journal:  Emerg Health Threats J       Date:  2015-04-15

Review 6.  Measles Epidemics in Romania: Lessons for Public Health and Future Policy.

Authors:  Stefan Dascalu
Journal:  Front Public Health       Date:  2019-04-25

7.  Measles resurgence in Brazil: analysis of the 2019 epidemic in the state of São Paulo.

Authors:  Cristina Makarenko; Alexandre San Pedro; Natalia Santana Paiva; Jefferson Pereira Caldas Dos Santos; Roberto de Andrade Medronho; Gerusa Gibson
Journal:  Rev Saude Publica       Date:  2022-06-13       Impact factor: 2.772

8.  Prevalence of measles antibodies among health care workers in Catalonia (Spain) in the elimination era.

Authors:  Luis Urbiztondo; Eva Borràs; Josep Costa; Sonia Broner; Magda Campins; José María Bayas; María Esteve; Angela Domínguez
Journal:  BMC Infect Dis       Date:  2013-08-26       Impact factor: 3.090

9.  Measles outbreak in Dubrovnik-Neretva County, Croatia, May to June 2018.

Authors:  Morana Tomljenovic; Mato Lakic; Tatjana Vilibic-Cavlek; Sanja Kurecic Filipovic; Vesna Visekruna Vucina; Andrea Babic-Erceg; Miljenko Ljubic; Iva Pem Novosel; Maja Ilic; Irena Tabain; Jelena Ivancic-Jelecki; Lisa Hansen; Bernard Kaic
Journal:  Euro Surveill       Date:  2020-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.